Current Oncology Reports

, 16:412 | Cite as

Anti-angiogenic Therapy Versus Dose-Dense Paclitaxel Therapy for Frontline Treatment of Epithelial Ovarian Cancer: Review of Phase III Randomized Clinical Trials

  • Katrina N. Slaughter
  • Kathleen N. MooreEmail author
  • Robert S. Mannel
Gynecologic Cancers (NS Reed, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Gynecologic Cancers


The investigation of anti-angiogenic agents and dose-dense paclitaxel therapy in epithelial ovarian cancer is an active area of research. To date several phase III trials have shown both approaches to be effective strategies for the frontline treatment of ovarian cancer over standard every 21 day chemotherapy alone. However, most of the improvement is seen only in progression-free survival, with added toxicity (e.g., hypertension, diarrhea, sensory neuropathy, fatigue). Subset analyses based on clinical predictors (e.g., residual disease) have been able to identify patients more likely to benefit from anti-angiogenic agents. And more recently, molecular profiling of tumor genetics has shown similar promising results. Ongoing research will help enhance our ability to match patients to therapeutic strategies most likely to optimize outcomes and minimize risk.


Ovarian cancer Anti-angiogenesis Oncology Dose dense Toxicity Gynecological cancer 


Compliance with Ethics Guidelines

Conflict of Interest

Katrina N. Slaughter declares no conflict of interest.

Kathleen N. Moore reports personal fees from Genentech, Immunogen, Advaxis, and Boehringer Ingelheim, outside the submitted work.

Robert S. Mannel has received grants and/or personal fees from Genentech, Amgen, AstraZeneca, Genentech, Endocyte, Eisai, Advaxis, Medimmune, and Oxigene.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


  1. 1.
    Siegal R, Ma J, Zou Z, Jemal A. Cancer Satistics, 2014. CA Cancer J Clin. 2014;64:9–29.CrossRefGoogle Scholar
  2. 2.
    Brown MR, Blanchette JO, Kohn EC. Angiogenesis in ovarian cancer. Bailliere’s best practice and research. Clin Obstet Gynaecol. 2000;14:901–18.Google Scholar
  3. 3.
    Burger RA. Overview of antiangiogenic agents in development for ovarian cancer. Gynecol Oncol. 2011;121:230–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Ferrara N. VEGF as a therapeutic target in ovarian cancer. Oncology. 2005;69 Suppl 3:11–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Gerald D, Chintharlapalli S, Augustin HG, Benjamin LE. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res. 2013;73:1649–57.PubMedCrossRefGoogle Scholar
  7. 7.
    Singh M, Ferrara N. Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat Biotechnol. 2012;30(7):648–57.PubMedCrossRefGoogle Scholar
  8. 8.
    Randall LM, Burger RA, Nguyen H, Kong G, Bookman MA, Fleming GF, et al. Outcome differences in patients with advanced epithelial ovarian, primary peritoneal and fallopian tube cancers treated with and without bevacizumab. Gynecol Oncol. 2013;130 (1);e33–e34.Google Scholar
  9. 9.
    Perren T, Swart AM, Pfisterer J, Ledermann JA, Pujade-Laurain E, et al. A phase III trial of bevacizumab in ovarian cancer. New Engl J Med. 2011;365:2484–96.PubMedCrossRefGoogle Scholar
  10. 10.
    Du Bois A, Floquet A, Weon Kim J, Rau J, Del Campo JM, Friedlander M, et al. Randomized double blind phase III trial of pazopanib versus placebo in women who have not progressed after first line chemotherapy for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16). J Clin Oncol. 2013;31(No 18 suppl; Abstr LBA 5503)Google Scholar
  11. 11.
    GlaxoSmithKline (GSK) Regulatory update: Votrient (pazopanib) as maintenance therapy for advancaed ovarian cancer in the EU. Accessed 31 Mar 2014
  12. 12.
    Du Bois A, Kristensen G, Ray-Coquard I, Reub A, Pignata S, Colombo N, et al. AGO-OVAR 12: A randomized placebo-controlled GCIG/ENGOT Intergroup phase III trial of standard frontline chemotherapy +/- nintedanib for advanced ovarian cancer. Int J of Gynecol Cancer. 2013;23(8 Suppl 1):7–8Google Scholar
  13. 13.
    Ledermann JA, Perren TJ, Raja FA, Embleton A, Rustin GJS, Jayson G, et al. Randomized double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial. European J of Cancer 2013;49(Suppl 3):Abract 10Google Scholar
  14. 14.
    A prospective, phase III, randomized, double blind placebo controlled trial evaluating adding trebananib to carboplatin and paclitaxel in the upfront treatment of patients with advanced stage ovarian cancer (NCT01493505). Accessed 6 Jun 2014.
  15. 15.
    Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, et al. A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1. European J of Cancer 2013;49(suppl 3):Abstract 41Google Scholar
  16. 16.
    Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, et al. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in firstline therapy of advance ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2014;32:1210–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase III randomized trial. Lancet Oncol. 2013;14:236–43.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Norton L. Theoretical concepts and the merging role of taxanes in adjuvant therapy. Oncologist. 2001;6 Suppl 3:30–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Belotti D, Vergani V, Drudis T, Borsotti P, et al. The microtubule-affecting drug pacilitaxel has antiangiogenic activity. Clin Cancer Res. 1996;2:1843–9.PubMedGoogle Scholar
  20. 20.
    Wang J, Lou P, Lesniewski R, Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs. 2003;14:13–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Klauber N, Parangi S, Flynn E, et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 1997;57:81–6.PubMedGoogle Scholar
  22. 22.
    du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundgvist E, et al. consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIGOCCC 2004). Ann Oncol. 2005;16 Suppl 8:viii7–12.PubMedGoogle Scholar
  23. 23.
    Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with tratuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008;26:1642–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Sparano JA, Wang M, Martino S, Jones V, Perez EA, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358:1663–71.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomized, controlled, open-label trial. Lancet. 2013;14:1020–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Chan J, Brady M, Penson RT, Monk B, Boente M, Walker J, et al. Phase III trial of every-3-weeks paclitaxel vs. dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT01167712). Int J of Gynecol Cancer 2013;23(8 suppl 1):9-10Google Scholar
  27. 27.
    Pignata S et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomized, multicenter, open-label, phase 3 trial. Lancet Oncol. 2013;15:396–405.CrossRefGoogle Scholar
  28. 28.
    An International Phase III Randomised Trial of Dose Fractionated Chemotherapy Compared to Standard Three Weekly Chemotherapy, Following Immediate Primary Surgery or as Part of Delayed Primary Surgery, for Women With Newly Diagnosed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT01654146). Accessed 18 Jul 2014.
  29. 29.
    Herzog TJ, Armstrong DK, Brady MF, Coleman RL, Einstein MH, et al. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol Oncol. 2014;132(1):8–17.PubMedCrossRefGoogle Scholar
  30. 30.
    Gourley C, McCavigan A, Perren T, Paul J, Michie CO, Churchman M, et al. Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. J Clin Onc 32:5s,2014;(suppl; abstr 5502)Google Scholar
  31. 31.
    Winterhoff BJN, Kommoss S, Oberg AL, Wang C, Riska SM, Konecny GE, et al. Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer. J Clin Oncol 32:5s, 2014;(suppl; abstr 5509)Google Scholar
  32. 32.
    The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–15.CrossRefPubMedCentralGoogle Scholar
  33. 33.
    Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27(9):1419–25.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43.PubMedCrossRefGoogle Scholar
  35. 35.
    Hertz DL, McLeod HL. Using pharmacogene polymorphism panels to detect germline pharmacodynamic markers in oncology. Clin Cancer Res. 2014;20:2530–40.PubMedCrossRefGoogle Scholar
  36. 36.
    Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. New Engl J Med. 2011;365:2473–83.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Katrina N. Slaughter
    • 1
  • Kathleen N. Moore
    • 1
    Email author
  • Robert S. Mannel
    • 1
  1. 1.Department of Obstetrics and GynecologyOklahoma University Health Sciences CenterOklahomaUSA

Personalised recommendations